About this trial
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Psilocybin
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Sham taVNS
Treatment groups
Sponsors and collaborators
Charles Raison
Lead sponsor
Vail Health Behavioral Health
Sponsor institution
Usona Institute
Collaborator
Tiny Blue Dot Foundation
Collaborator
Steadman Philippon Research Institute
Collaborator
Emory University
Collaborator